Summary

Eligibility
for people ages 2-65 (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

This Phase 4 study will evaluate the safety and tolerability of Fabrazyme at current approved dose with increases in the infusion rate and reduced infusion volume. This study aims to generate data to provide the guidance on how infusion rate can be safely increased and minimize the burden of the life-long treatment with Fabrazyme.

Official Title

A Study to Investigate Safety and Tolerability of Higher Infusion Rate to shORten the duraTion of FabrazymE Infusion

Details

The total duration will be up to 6 months

Keywords

Fabry's Disease, Fabry Disease, Acetaminophen, Diphenhydramine, Promethazine, Dexamethasone, Montelukast, AGALSIDASE BETA (GZ419828), agalsidase beta

Eligibility

You can join if…

Open to people ages 2-65

  • Participants with confirmed diagnosis of FD who are ≥2 and ≤65 years of age at the time of signing the informed consent form (ICF) or assent, if applicable.
  • Cohort 1: female participants with body weight ≥30 kg who have been treated with Fabrazyme for at least 3 months without IARs during the most recent 3 infusions.
  • Cohort 2: non-classic male participants with body weight ≥30 kg who have been treated with Fabrazyme for at least 3 months without IARs during the most recent 3 infusions.
  • Cohort 3: classic male participants with body weight ≥30 kg who have been treated with Fabrazyme for at least 3 months without IARs during the most recent 3 infusions.
  • Cohort 4: participants with body weight <30 kg who have been treated with Fabrazyme for at least 3 months without IARs during the most recent 3 infusions.
  • Cohort 5: ERT-naïve participants. Women of childbearing potential must use a highly effective method of contraception through the study.

You CAN'T join if...

  • Female participants who are pregnant or breastfeeding.
  • History of significant allergic disease or hypersensitivity to Fabrazyme or other medicinal products.
  • Contraindication to Fabrazyme or any of the premedications or rescue medications (diphenhydramine, acetaminophen, montelukast, dexamethasone).
  • Any other medical condition considered to make the increased infusion rate not tolerable at the Investigator's discretion. The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Locations

  • UCLA Medical Center Site Number : 1003 accepting new patients
    Santa Monica California 90404 United States
  • Infusion Associates Site Number : 1001 accepting new patients
    Grand Rapids Michigan 49525 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Sanofi
ID
NCT06019728
Phase
Phase 4 Fabry Disease Research Study
Study Type
Interventional
Participants
Expecting 18 study participants
Last Updated